

1 Subgrouping patients with comorbidity between functional dyspepsia 2 and irritable bowel syndrome: application of multidimensional item 3 response theory and latent profile analysis

4 Huang Zhongyu^{1,2#}, Lyu Zipan^{2,3}, Liu Fengbin²

- 5 1. Guangzhou First People's Hospital, School of Medicine, South China University of Technology,
6 Guangzhou 510000, Guangdong, China.
- 7 2. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000,
8 Guangdong, China.
- 9 3. Nanyang Technological University, Singapore.

10
11 #Corresponding author: ZY.HUANG::zy1717086@163.com.

12 13 Abstract

14 **Background:** Comorbidity between different subtypes of functional gastrointestinal disorders(FGIDs)
15 is of high prevalence in clinical practice. Heterogeneity of clinical appearances has led to difficulty in
16 individualized diagnosis and comprehensive management of FGIDs.

17 **Aims:** To discover the hidden clinical patterns of patients with comorbidity between functional
18 dyspepsia(FD) and irritable bowel syndrome(IBS).

19 **Methods:** In a retrospective cross-section study, a self-report questionnaire that consist of items
20 indicating 5 different assessing domains including gastrointestinal discomforts, systemic discomforts,
21 psychological disorders, and environmental aggravated factors was used as basic instrument for clinical
22 assessment. With item response theory, the theoretical framework of assessment was evaluated, and
23 latent traits of patient were quantified in the simulated computerized adaptive testing. Latent class
24 analysis was used for uncovering the hidden patterns over the heterogenous clinical appearances. And
25 differences among the profiles were compared referring to the spectrum of clinical appearances and the
26 clinical diagnosis.

27 **Results:** With 996 patients enrolled in the study, the validity and reliability of the instrument were
28 evaluated as adequate (Cronbach's alpha indices =0.72, Split-half reliability =0.84). The construct
29 validity was also evaluated to be adequate with Chi-square/df=3.45, CFI=0.92, GFI=0.96,
30 RMSEA=0.05, TLI=0.90, RMR=0.02. The 7-profile model was evaluated to be with better fitness with
31 Entropy=0.98, Lo-Mendell-Rubin likelihood ratio test-*p* value<0.01, Bootstrap likelihood ratio test-*p*
32 value<0.01. And the patterns detailed the heterogeneity of clinical appearance of FGIDs patients either
33 in general condition or discomfort in specific dimension.

34 **Conclusions:** With application of multidimensional variable analysis, this article summarized the
35 hidden patterns beneath the heterogenous clinical features. And quantitative approaches helped equip
36 clinician with individualized and comprehensive tool in the management of complex diseases such as
37 FGIDs.

38
39 **Keywords:** Irritable bowel syndrome; Functional dyspepsia; Latent profile modeling; Item response
40 theory; Computerized adaptive testing

41 **Introduction**

42 Characterized by persistent and recurring gastrointestinal symptoms, functional gastrointestinal
43 disorders (FGIDs) affected people with a prevalence over 40% around the world(1, 2). Although Rome
44 III and IV criteria are widely used for diagnosis of FGIDs in research design and clinical practice, it
45 leads to underdiagnosis and misdiagnosis of patients without capturing the full spectrum of their
46 symptoms(3). The heterogeneity and variability of clinical manifestations of FGIDs pose a challenge
47 for individualized diagnosis, which in turn hinders the attainment of satisfied efficacy of treatment(4).

48 The prevalence of overlapping among FGIDs subtypes was also reported to be high, especially that
49 between functional dyspepsia(FD) and irritable bowel syndrome(IBS)(5-7). Similar symptoms between
50 IBS and FD such as abdominal pain, bloating and changes in bowel habits make it difficult to make
51 comprehensive diagnosis and differentiation of the two conditions(8). Relying on self-reported
52 symptoms, it is difficult to make a definitive diagnosis with clinical criteria such as Rome IV. Common
53 pathophysiological mechanism that contributed to both FD and IBS were reported involving the
54 dysfunction of gastrointestinal motility(9, 10), visceral hypersensitivity(11), immune activation(12),
55 abnormal brain-gut interaction(13) and psychosocial factors(14). However, the lack of objective
56 biomarkers makes it difficult to confirm a diagnosis with certainty. Comorbidities with different
57 subtypes of FGIDs and non-gastrointestinal disorders reminds clinician to consider a comprehensive
58 approach while diagnosing and treating patients with FGIDs.

59 Aiming at shifting towards a more individualized and comprehensive mode in treating FGIDs, in recent
60 decades, quantitative instruments and patient-centered care models were developed for assisting
61 decision-making in clinical practice(15). Scales were developed for measuring multidimensional
62 clinical appearances including gastrointestinal somatic symptoms, extraintestinal somatic symptoms
63 and psychological symptoms(16, 17). From interdisciplinary perspective, data science methods were
64 applied to discover latent patterns beneath the complex clinical appearances of diseases(18, 19). As
65 typical strategy, principal component analysis and latent class analysis(LCA) were normally used for
66 identifying subgroups of FGIDs via clustering symptoms and extracting relationship among the
67 complex clinical appearance(20-22). Advanced applications were also developed over the quantitative
68 approaches. Informatic platforms such as Rome IV multidimensional clinical profile (MDCP) and
69 Interactive Clinical Decision Toolkit were also developed to assist clinical decision and individualized
70 comprehensive management of FGIDs(23-25). Although the application of these tools represent a
71 significant paradigm shift in the field FGIDs assessment and treatment the adaptation of the assessing
72 procedure and interpretability of the assessing results were to be optimized for further application in
73 clinical practice(26). Moreover, due to the regional differences derived from different countries and
74 ethnicity, it is crucial to develop patient-centered and condition adaptive instruments to meet the need
75 of regional practice in assessing FGIDs.

76 Innovated testing theory and algorithm such as multidimensional item response theory (MIRT) and
77 structural equation modelling (SEM) were applied for enhancing feasibility and interpretability of the
78 assessment in specific occasion(27, 28).In these paradigm, conceptual framework could be constructed
79 and validated with SEM and psychometric properties of the instrument could be estimated with MIRT.
80 With a flexible framework, computer adaptive testing(CAT) on basis of MIRT also revealed adaptively
81 quantification of examinees' latent traits in an more efficient way(29, 30). Taking advantage of these

82 multidisciplinary approaches, this article attempted to estimate an innovative methodological paradigm
83 for individualized assessment of patients with comorbidity of FD and IBS.

84 **Materials and methods**

85 **Self-report questionnaire and assessing framework**

86 Through a comprehensive review on the clinical prevalence of FGIDs related symptoms, an item pool
87 was constructed referring 5 regional experts' consensus and clinical guidance about FD and IBS
88 published in Asia(31-35). Content of items was designed referring to the setting of scales including
89 IBS-SSS(36) and SF-36(37). Following guidance of ROME IV criteria, option setting of each item was
90 designed and illustrated in 4-points Likert style. For the category of symptom intensity, option 0
91 indicates inapplicable and 1 indicates Mild degree fitting those symptoms are not quite apparent and
92 attack once a week. For Moderate with score 2, symptoms are apparent but do not disrupt daily
93 activities which occur 2-3 days in a week. Severe degree with score 3 implicated that symptoms are
94 apparent and strongly interfere with daily life which occur 4-5 days or more in a week. For the
95 non-gastrointestinal factors including dietary, environmental, and mental factors, dichotomous items
96 were designed to discriminate inductive and alleviate factor associated with clinical discomforts.
97 Cultural adjustment process was carried out with a group discussion among clinical practitioners and
98 experts. And symptoms such as "abdominal cold" and "overwork aggravated discomfort" that not
99 specified in Rome criteria were drafted and added in the assessment considering the regional
100 prevalence in China. Finally, the questionnaire was designed consisting of 26 items over a theoretical
101 framework covering five latent traits including gastrointestinal symptoms, systemic symptoms,
102 environmental sensitivity, and emotional discomforts.

103 **Participants**

104 A cross-sectional study was designed for collecting clinical features of patients diagnosed with FD or
105 IBS according to Rome IV criteria. Diagnosis was made by the senior clinic practitioner after ruling out
106 potential organic lesions with gastrointestinal endoscopy. Patients were enrolled after consent
107 following introduction of staff in research center from Oct 2017 to Dec 2019 in the first affiliated
108 hospital of Chinese medicine. Severity of symptoms spectrum together with clinical diagnosis of each
109 case were recorded with the self-administrated questionnaire for further analysis. As exclusion criteria,
110 patients with organic disease and those with severe systemic disease or with history of drug or alcohol
111 abuse were not enrolled in this study. Those with incapacity to cooperate throughout the research
112 process were also eliminated ensuring the quality of response. The study protocol was approved by the
113 Ethical Committee of the First Affiliated Hospital of Chinese Medicine (NO.AF/JD-01/05).

114 **Data management and Statistical Analysis**

115 Record of the paper-based questionnaires was typed and validated in Excel with cooperation of two
116 staffs. With validation of a third staff, conflicting records were confirmed and corrected. The tolerance
117 of missing rate of each case was set as 5% by which cases were regarded as low-quality and to be
118 eliminated.

119 Reliability of the assessment was evaluated with Cronbach's alpha indices that calculated in SPSS 21.0.
120 As shown in Table 1, the theoretical model was constructed consisting of 5 dimensions including
121 systemic symptoms, upper gastrointestinal symptoms, lower gastrointestinal symptoms, environmental
122 sensitivity and emotional disorders. The structural validity of the theoretical framework was evaluated
123 with Confirmatory factor analysis (CFA) in AMOS 21.0. And model fitting indices were evaluated

124 including Goodness of Fit Index(GFI), Comparative Fit Index(CFI), Root Mean Square Error of
125 Approximation(RMSEA), Root Mean Square Residual(RMR) and Tucker Lewis Index(TLI).

126 As the basic model for the CAT development, psychometric properties of each item were estimated
127 with MIRT in R 3.2.4. And multidimensional discrimination indices (MDISC) of each item and its
128 standardized factor loadings on latent traits were evaluated with R package mirt(38).

129 On basis of the MIRT model, the CAT was developed with following setting: (i). Initialization: initial
130 values about each dimension was set as 0 and in range of (-3,3) before the starting of the assessment.
131 (ii)Scoring: Maximum a-posterior (MAP) algorithm was used for estimating factor score with
132 quasi-Monte Carlo integration. (iii).Point-wise Kullback-Leibler criteria was set as the rule for item
133 selection(39). (iv). Stopping: with a simulated procedure, the test terminated when all items were
134 answered or SE of all latent scores were less than 0.3.

135 Latent profile analysis(LPA) was used for estimating subgroups of the sample based on the
136 multidimensional latent trait scores from CAT in Mplus 7.4 and R 3.2.4. In a larger scale of assessing
137 granularity, a latent class model on basis of original responses of items was also estimated. Gaussian
138 Mixture modelling(40) was set as the algorithm for estimating models with different number of profiles.
139 Goodness of fit indices were estimated and compared among models including Log-Likelihood(Loglik),
140 Akaike Information Criteria(AIC), Bayesian Information Criteria(BIC), Sample Adjusted BIC(SABIC),
141 Entropy, Bootstrap likelihood ratio test(BLRT) and Lo-Mendell-Rubin likelihood ratio test(LMRT).
142 And the one with most adequate fitness indices was selected for further analysis.

143 Comparison between IBS and FD in demographic descriptors was evaluated using Pearson's
144 Chi-square analysis or ANOVA in R 3.2.4. Mann-Whitney U test was used for comparing the original
145 response of each item between FD and IBS. Moreover, intensity of symptoms and estimated scores of
146 latent traits in the LPA models were compared using Kruskal-Wallis H test followed up by post-hoc
147 test for pairwise comparisons of subgroups with Nemenyi's test.

148 **Result**

149 **1. Participants**

150 There were 1124 patients participating in the research. And 996 cases were finally enrolled meeting the
151 inclusion criteria with the other 128 cases eliminated out of data incompleteness. As shown in Table 2,
152 the enrolled sample consisted of 487 IBS patients and 509 FD patients according to their primary
153 clinical diagnosis. And female took up a larger proportion than male (53.41% vs 46.59%). However,
154 the difference of sexual was evaluated to be none statistically significant with Pearson's Chi-squared
155 test($p=0.935$). The average age of the sample was 38.47 with range 18 to 74. And 425 of the enrolled
156 people suffered from FGIDs related discomforts for 1 to 3 years that took up a larger proportion than
157 others.

158 Subgrouping by original diagnosis, clinical features were compared between FD and IBS and the
159 results were shown in Table 3. There were statistical differences existing in the typical symptoms
160 conspicuously for the diagnosis of FD and IBS including bloating, belching, heartburn, nausea,
161 diarrhea, lower abdominal pain, loose stool, hyperactive bowel sounds, urgency, discomforts
162 aggravated by irregular diet together with systemic symptoms such as back pain and joint pain with
163 $p<0.05$ in the Mann-Whitney U test. Other symptoms and predisposing factors were evaluated to be
164 none significantly different between the two groups of patients.

165 **2. Validity and reliability**

166 Validity and reliability of the self-report questionnaire was evaluated to be adequate. Cronbach's alpha
167 coefficient of all items of the instrument was evaluated to be 0.72 with the split half reliabilities to be
168 0.84. In CFA, the construct validity of the instrument was also evaluated to be adequate with
169 Chi-square/df=3.45, CFI=0.92, GFI=0.96, RMSEA=0.05, TLI=0.90, RMR=0.02 in CFA. Further
170 psychometric properties including MDISC and factor loadings indices of each item were evaluated in
171 MIRT and shown in Table 4. Most items were evaluated to be with a significant loading over 0.3 with
172 related factors. And the discrimination property of the items was evaluated to be consistent with
173 clinical observation. For the systemic discomforts, fatigue and insomnia hold the highest factor loading
174 indices and MDISC indices. It indicated that insomnia and fatigue could be used for characterizing
175 patient subgroup with distinguishable property. Similarly, discrimination of bloating, nausea,
176 abdominal cold, heartburn and early fullness as typical upper gastrointestinal discomforts were also
177 evaluated to be adequate while belching and upper abdominal pain were in a lower level. However,
178 comparison about three typical symptoms that known as subtype-specific between FD and IBS showed
179 not significant differences in their severity distribution (abdominal cold($p=0.71$), upper abdominal
180 pain($p=0.37$) and early fullness($p=0.08$)) as shown in Table3. All lower gastrointestinal symptoms
181 were evaluated to be with significant difference in intensity with adequate discrimination property
182 comparing between IBS and FD. And the Z-score of symptoms in IBS were higher than that in FD
183 subtype. As to the environmental sensitivity factor, discomforts triggered by indigestive food were
184 evaluated with highest factor loading indicating it as the most reported discomforts of both FD and IBS.
185 There was no difference evaluated among symptoms in psychological comorbidity factors between FD
186 and IBS as shown in Table 3. And anxiety was evaluated with the highest factor loading while stress
187 taking the lowest one as shown in Table4.

188 **3. Latent class model with original responses**

189 To discover the hidden patterns beneath the heterogenous clinical appearances, latent class model was
190 estimated with original intensity records of clinical symptoms. Clustering over the original response of
191 the assessment, subgroups was defined the spectrum of symptoms in various intensity. The latent class
192 model with 3 classes was evaluated to be adequate with $p\text{-LMRT}<0.05$ comparing with the 4-class
193 model as shown in Table 5. Intensity of clinical features of each estimated subgroup were plotted in
194 Figure 1. The first subgroup was identified with higher severity in systemic discomforts and upper
195 gastric symptom than the other 2 subgroups. And patients in this subgroup suffered much pain and are
196 more likely to be affected by environmental factors such as indigestive food. However, these people
197 suffered more severe anxiety than depression. Different from Class 1, patients in the Class 2 suffered
198 from more serious mental discomforts but less pain symptoms. Moderate level of intensity of upper
199 gastrointestinal symptoms were evaluated as statistically significant($p<0.05$) including bloating,
200 belching, and early satisfy comparing with the other two subgroups as shown in Table 6. Upper gastric
201 tract appearances were much typical including belching, bloating, and early fullness. Identified with
202 higher intensity of lower gastrointestinal discomfort, patients in the Class 3 showed more serious
203 symptoms including diarrhea, lower abdominal pain and hyperactive bowel sounds and their upper
204 gastrointestinal symptoms were less serious than the other 2 subgroups. Higher intensity of diarrhea
205 and lower gastrointestinal pain and lower intensity in symptoms including bloating, heartburn, belching,
206 early fullness, and urgency were evaluated with difference($p<0.05$) comparing with the Class 2.

207 Clinical diagnosis of these 3 subgroups were also evaluated as the result shown in Table 7. For the
208 Class 1, FD and IBS took up proportions with 39.73% and 60.27%. And FD took up proportion of
209 84.60% in the Class 2 while IBS taking up 82% in the Class 3. The proportion of diagnosis among the
210 subgroups was evaluated to be of significant difference in the Pearson's Chi-square analysis($p < 0.001$)
211 as shown in Table 7. The pattern of clinical appearances and mixture of subtypes in the groups
212 indicated the possible incompleteness of diagnosis of patients with more than one FGIDs subtypes.
213 And it is also important to consider the comprehensive spectrum of symptoms so that we could better
214 interpret the complexity of gut-brain interaction from the clinical cases.

215 **4. Latent profiles modelling with multidimensional trait scores**

216 Summarizing different discomforts into 5 latent traits, multidimensional scores of each patient were
217 estimated and scaled in the stimulated CAT as shown in Table 8. As all latent traits were estimated in a
218 continuous format, LPA was used to clustering subgroups of the patients. As shown in Table 9, the
219 model with 7 profiles was evaluated as adequate with lower BIC value. And the value of LMRT was
220 evaluated as -197.71 ($p > 0.05$) as comparison between the 7-profile model to the 8-profile model.
221 Referring to the proportion of clinical subtypes, difference among the 7 subgroups was evaluated to be
222 without statistical significance with Chi-square=11.391($p = 0.08$) as shown in Table 10. In total, there
223 were 875 patients in subgroup P1, P2, P3 and P6 taking up 87.85% of the sample accumulatively.
224 Different patterns of the latent traits could be observed among the 7 subgroups of FGIDs characterized
225 by different scores of latent traits as shown in Figure 2.

226 Heterogeneity of the patterns reflected in both overall condition of the latent traits scores and intensity
227 of distinct appearance. For example, in both the P1 and the P4 subgroups, general scores of latent traits
228 were evaluated to be lower comparing to other subgroups. And multidimensional severity of the P5
229 subgroup was evaluated with a generally higher condition. As to the P2 subgroup, score of systemic
230 symptoms was higher than those of other traits. And patients in the P3 subgroup were assessed with a
231 high score in the environmental sensitivity dimension. In P5, P6 and P7 subgroups, higher score in GI
232 discomforts were assessed comparing with the average condition of the subgroups. It could be observed
233 that score of mental discomforts were positively correlated with that of the systemic discomforts in all
234 subgroups. The differences among these 7 subgroups indicated the heterogeneity of clinical appearance
235 of FGIDs. And the covariation between different traits provided clues for interpreting the complexity of
236 pathogenesis of FGIDs such as gut-brain interaction.

237 **Discussion**

238 Although the Rome criteria provided guidance for categorizing FGIDs with typical symptom spectrum,
239 clinical management of FGIDs is still challenging out of the heterogeneity and variability of clinical
240 appearances of patients. The criteria for categorizing FGIDs also showed limitation due to the mixture
241 of the clinical manifestations between different subtypes. As the results shown in this study, patients
242 with FD and IBS were reported to suffer from common discomforts including gastrointestinal
243 symptoms, systemic symptoms, and environmental sensitivity in clinical practice. It's also evaluated
244 that patient with FD and IBS commonly suffered from mental discomforts including anxiety and
245 irritating. The overlapping of symptoms between FD and IBS evaluated in this study showed
246 consistency with that reported in previous clinical study(7, 41). Although the pathogenesis about the
247 comorbidity is not well interpreted. Some biological hypotheses could help explaining the
248 phenomenon. Disorder of gut-brain interact bidirectionally plays a crucial role in the pathophysiology

249 of both FD and IBS(42). By using MRI or PET scanning, researchers have found that central nervous
250 system alterations regionally existed in these two diseases(43, 44). Previous studies showed the
251 homeostasis of mucosal cytokines and gut-homing T lymphocytes were disrupted in both FD and
252 IBS(12, 45). It was also proposed that the comorbidity could be associated with hypersensitivity,
253 motility abnormalities in gastrointestinal tract. The possible mechanism of this phenomenon could be
254 about altered function of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous
255 system(46).

256 In this study, two models with different assessing granularity were estimated by summarizing
257 comprehensive gastrointestinal symptoms and comorbidity with systemic symptoms and emotional
258 disorders. As poor concordance between the data-driven clustering results and the clinical diagnosis
259 was evaluated in both models, it reminded us of the importance of making a comprehensive assessment
260 and diagnosis of patients with FGIDs. Following Rome criteria, patients with typical anatomical
261 discomforts could be easily categorized and diagnosis. However, heterogeneity of the spectrum and
262 severity of discomforts reflect the need to develop individualized assessment in a proper scale to assist
263 assessment in clinical practice. Using multidimensional variable analysis approaches, patients with
264 FGIDs could be varied into different subgroups according to the severity of clinical appearances(47).
265 And the patterns of clinical appearances supported the concept that FGIDs subtypes such as functional
266 bowel disorders should be treated as clinical continuum, other than separate disorders(48). And the
267 systemic pathogenesis should be well inferred and summarized for better management of FGIDs other
268 than following the anatomical classification and diagnosis criteria rigidly(49).

269 Heterogeneity and instability of clinical appearance also made it difficult to establish a comprehensive
270 criteria or instrument with adequate stability and interpretability for FGIDs diagnosis. Prevalence of
271 clinical features were reported to be different between different regions. Fluctuation of FGIDs
272 symptoms brought difficulty for individual evaluation and treatment decision in clinical practice. As a
273 regional specific symptom of the study, “abdominal cold” was recorded with high prevalence in China.
274 It was also normally seen that patients without medical knowledge would report ambiguous position or
275 property. That bring difficulty in clinical assessment and reminded us of the importance of the
276 civilization background for the designation of instrument.

277 Relying on the similarity about symptoms spectrum and their severity, LPA and LCA served as
278 data-driven methods for discovering patterns of clinical appearances of patients with comorbidity
279 between FD and IBS. The composition of FGIDs subtype in the 3-class LCA model indicated the
280 impracticability of Rome criteria in comprehensive assessment of patients. Neither FD nor IBS could
281 be well described with the spectrum of the symptoms in each subgroup. The patterns of clinical
282 appearances estimated in this study also indicated the complexity about the pathophysiology of FD and
283 IBS. As shown in the 7-class LPA model, not only the severity of gastrointestinal symptoms but also
284 the comorbidity with psychological and systemic discomforts should be evaluated as clues for the
285 subgrouping patients with FD and IBS. Although the interaction between somatic discomfort and
286 mental discomfort was not well evaluated in this study due to the lack of data from cohort study,
287 covariation of the scores between mental discomfort and systemic discomfort could be observed. It was
288 reported that the gut-brain interaction could serve as an important pathogenesis in the development of
289 FGIDs. And it has become a consensus of clinical practitioners to consider the impact of mental
290 disorders while treating patients with FGIDs. The analytic paradigm raised in this study revealed

291 discovery of the hidden pattern of clinical appearances of patients with comorbidity between FD and
292 IBS. However, interpretation of the model is limited due to the lack of representative data from cohort
293 design. The model should be further optimized for better representing the pathogenesis and possible
294 evolution among different FGIDs subgroups.

295 Although there were many instruments developed for subgrouping FGIDs subtypes in form of
296 scales(18, 50), the compensatory of calculation with accumulating response scores overlaid the details
297 about individuals and further diminished the interpretation of the assessment. With development of
298 CAT, multidimensional latent traits were quantified as summarized mixture of symptoms. Collectively
299 focusing on the universe of clinical appearances may yield significant benefits for FGIDs patients with
300 comprehensive individualized instruments for clinical assessment. With the CAT estimated on the
301 5-dimensional MIRT model, latent traits of each patient were evaluated for upper and lower
302 gastrointestinal discomforts, severity of emotional disorder, systemic severity and environmental
303 sensitivity. It benefited the practitioner with comprehensive individual evaluation in a more
304 interpretable conceptual framework. Moreover, via comparison between the 3-class model and the
305 7-profile model, the paradigm also provide flexible setting of granularity of assessment that could be
306 adaptively optimized to fit the need of clinical practice.

307 With integrative application multivariable analysis methods, this article proposed an innovative
308 paradigm for subgrouping FGIDs with multi-scale assessing framework. Taking personal traits other
309 than symptoms clusters as parameters, the interpretation of the model was also strengthened for clinical
310 practice. However, there are several limitations in our research. Firstly, a cross-section study was
311 designed and all patients enrolled in this study were from single research center. More convincing
312 conclusion could be drawn with a more representative sample of FGIDs patients. Further research
313 should also be carried out for validating the stability, rationality, and further extrapolation of the model.
314 Secondly, although the self-report questionnaire was designed via a strict procedure, the setting of
315 items together with their psychometric properties should be optimized and re-validated in further
316 research. In this way, the interpretability and extrapolation of the latent profile models could be
317 modified via reducing bias that introduced from an unrepresentative sample. Thirdly, the
318 generalizability of the findings also limited since all data was collected from China and some culturally
319 specific items were designed such as “abdominal cold” was designed for assessment. Last but not the
320 least, assessing logic about the CAT could also be optimized by analyzing and comparing the time cost
321 and consistency among different settings of assessment.

322 **Conclusion**

323 Making a comprehensive assessment about clinical features of FGIDs patients, this study raised a new
324 subgrouping model for FD and IBS making use of multivariable analysis method such as CAT and
325 LPA. The heterogenous appearances of FD and IBS patients was profiled into 7 subgroups according to
326 the severity and the spectrum of symptoms including gastrointestinal symptoms, systemic symptoms,
327 and environmental factors. The results suggested that criteria together with instruments need to be
328 updated so as to make comprehensive individualized assessment of FGIDs patients. Furthermore,
329 interdisciplinary strategy benefited clinicians with quantitative and automatic approaches for
330 comprehensive evaluating and managing FGIDs patients which we believed would shift the clinical
331 practice to a much more individualized mode with flexibility and availability.

332

333 **Declarations**

334 **Ethics approval and consent to participate.**

335 All patients enrolled in this study signed informed consent. And this work was approved by the Clinical
336 Research and Ethics Committee at the First affiliated Hospital of Guangzhou University of Chinese
337 Medicine. (NO.AF/JD-01/05)

338

339 **Competing Interest**

340 The authors declare that there is no conflict of interest regarding the publication of this article.

341

342 **Authors' Contributions**

343 ZY.H and ZP.L contributed toward the concept, data analysis, and manuscript writing, and manuscript
344 review; ZY.H and ZP.L contributed toward patient and data collection; ZY.H, ZP.L, and FB.L
345 contributed toward funding, concept, and manuscript review.

346

347 **Funding**

348 This study was supported by the Guangdong Basic and Applied Basic Research
349 Foundation(No.2023A1515011432), the Guangzhou Science and Technology Planning Project
350 (No.2023A04J0627), the Natural Science Foundation of China (No.82004256, No.81774264) and the

351 China Postdoctoral Science Foundation (No. 2021M691263) .

352

353 **Acknowledgments**

354 The authors sincerely acknowledge the Guangzhou library for offering digital materials and rooms as
355 essential support for the study.

356

357 **Data Availability Statement**

358 The data used to support the findings of this study are available from the first
359 author(mail:zy1717086@163.com) upon request.

360

361

362

363 **Reference**

- 364 1. Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders:
365 advances in understanding and management. *The Lancet*. 2020;396(10263):1664-74.
- 366 2. Sperber AD, Bangdiwala SJ, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide
367 Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global
368 Study. *Gastroenterology*. 2021;160(1):99-114.e3.
- 369 3. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features,
370 and Rome IV. *Gastroenterology*. 2016;150(6):1262-79. e2.
- 371 4. Lin LD, Chang L. Using the Rome IV Criteria to Help Manage the Complex IBS Patient. *Official
372 journal of the American College of Gastroenterology | ACG*. 2018;113(4):453-6.
- 373 5. Nakov R, Dimitrova-Yurukova D, Snegarova V, Uzunova M, Lyutakov I, Ivanova M, et al. Prevalence
374 of Irritable Bowel Syndrome, Functional Dyspepsia and their Overlap in Bulgaria: a Population-Based
375 Study. *J Gastrointestin Liver Dis*. 2020;29(3):329-38.
- 376 6. Park H. Functional gastrointestinal disorders and overlap syndrome in Korea. *J Gastroenterol
377 Hepatol*. 2011;26 Suppl 3:12-4.
- 378 7. von Wulffen M, Talley NJ, Hammer J, McMaster J, Rich G, Shah A, et al. Overlap of Irritable Bowel
379 Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. *Dig Dis Sci*.
380 2019;64(2):480-6.
- 381 8. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. Epidemiology, clinical
382 characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA,
383 Canada, and the UK: a cross-sectional population-based study. *The lancet Gastroenterology &
384 hepatology*. 2018;3(4):252-62.
- 385 9. Carbone F, Fikree A, Aziz Q, Tack J. Joint Hypermobility Syndrome in Patients With Functional
386 Dyspepsia. *Clin Transl Gastroenterol*. 2020;11(11):e00220.
- 387 10. Tanaka Y, Kanazawa M, Palsson OS, Tilburg MAV, Gangarosa LM, Fukudo S, et al. Increased
388 Postprandial Colonic Motility and Autonomic Nervous System Activity in Patients With Irritable Bowel
389 Syndrome: A Prospective Study. *J Neurogastroenterol Motil*. 2018;24(1):87-95.
- 390 11. Simrén M, Törnblom H, Palsson OS, van Tilburg MAL, Van Oudenhove L, Tack J, et al. Visceral
391 hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings
392 from five different patient cohorts. *Gut*. 2018;67(2):255-62.
- 393 12. Burns G, Carroll G, Mathe A, Horvat J, Foster P, Walker MM, et al. Evidence for Local and Systemic
394 Immune Activation in Functional Dyspepsia and the Irritable Bowel Syndrome: A Systematic Review.
395 *Am J Gastroenterol*. 2019;114(3):429-36.
- 396 13. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction.
397 *Gastroenterology*. 2016;150(6):1257-61.
- 398 14. Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, Drossman DA, et al. Psychosocial
399 aspects of the functional gastrointestinal disorders. *Gastroenterology*. 2006;130(5):1447-58.
- 400 15. Dipesh HV, Peter AP, Christopher JB, Lesley AH, Hazel AE, Maura C, et al. British Society of
401 Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70(7):1214.
- 402 16. Gierk B, Kohlmann S, Kroenke K, Spangenberg L, Zenger M, Brähler E, et al. The somatic symptom
403 scale-8 (SSS-8): a brief measure of somatic symptom burden. *JAMA internal medicine*.
404 2014;174(3):399-407.

- 405 17. Kanazawa M, Nakajima S, Oshima T, Whitehead WE, Sperber AD, Palsson OS, et al. Validity and
406 reliability of the Japanese version of the Rome III diagnostic questionnaire for irritable bowel
407 syndrome and functional dyspepsia. *J Neurogastroenterol Motil.* 2015;21(4):537.
- 408 18. Bouchoucha M, Devroede G, Fysekidis M, Rompteaux P, Sabate JM, Benamouzig R. Data Mining
409 Approach for the Characterization of Functional Bowel Disorders According to Symptom Intensity
410 Provides a Small Number of Homogenous Groups. *Digestive Diseases.* 2020;38(4):310-9.
- 411 19. Berens S, Engel F, Gauss A, Tesarz J, Herzog W, Niesler B, et al. Patients with Multiple Functional
412 Gastrointestinal Disorders (FGIDs) Show Increased Illness Severity: A Cross-Sectional Study in a Tertiary
413 Care FGID Specialty Clinic. *Gastroenterol Res Pract.* 2020;2020:9086340.
- 414 20. Polster AV, Palsson OS, Törnblom H, Öhman L, Sperber AD, Whitehead WE, et al. Subgroups of IBS
415 patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report
416 differences in healthcare utilization: A population-based study. *Neurogastroenterology & Motility.*
417 2019;31(1):e13483.
- 418 21. Polster A, Van Oudenhove L, Jones M, Öhman L, Törnblom H, Simrén M. Mixture model analysis
419 identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal,
420 extraintestinal somatic and psychological symptoms. *Alimentary Pharmacology & Therapeutics.*
421 2017;46(5):529-39.
- 422 22. Siah KTH, Gong X, Yang XJ, Whitehead WE, Chen M, Hou X, et al. Rome Foundation-Asian working
423 team report: Asian functional gastrointestinal disorder symptom clusters. *Gut.* 2018;67(6):1071-7.
- 424 23. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for Irritable Bowel
425 Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to
426 Evaluate Efficacy and Safety. *Official journal of the American College of Gastroenterology | ACG.*
427 2012;107(11):1702-12.
- 428 24. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in
429 patients with constipation-associated irritable bowel syndrome--results of two randomized,
430 placebo-controlled studies. *Aliment Pharmacol Ther.* 2009;29(3):329-41.
- 431 25. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features,
432 and Rome IV. *Gastroenterology.* 2016;150(6):1262-79.e2.
- 433 26. Ghoshal UC. Marshall and Warren Lecture 2019: a paradigm shift in pathophysiological basis of
434 irritable bowel syndrome and its implication on treatment. *Journal of Gastroenterology and*
435 *Hepatology.* 2020;35(5):712-21.
- 436 27. Huang Z, Lyu Z, Hou Z, Wu Y, Huang J, Liu F, et al. Quantifying Liver-Stomach Disharmony Pattern
437 of Functional Dyspepsia Using Multidimensional Analysis Methods. *Evidence-Based Complementary*
438 *and Alternative Medicine.* 2020;2020.
- 439 28. Dowling NM, Bolt DM, Deng S, Li C. Measurement and control of bias in patient reported
440 outcomes using multidimensional item response theory. *BMC Medical Research Methodology.*
441 2016;16(1):63.
- 442 29. Goldenberg JZ, Steel A, Day A, Yap C, Bradley R, Cooley K. Naturopathic approaches to irritable
443 bowel syndrome: protocol for a prospective observational study in academic teaching clinics.
444 *Integrative Medicine Research.* 2018;7(3):279-86.
- 445 30. Chalmers RP. Generating adaptive and non-adaptive test interfaces for multidimensional item
446 response theory applications. *Journal of Statistical Software.* 2016;71(5):1-39.

- 447 31. Miwa H, Ghoshal UC, Fock KM, Gonlachanvit S, Gwee KA, Ang TL, et al. Asian consensus report
448 on functional dyspepsia. *Journal of gastroenterology and hepatology*. 2012;27(4):626-41.
- 449 32. Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, et al. Asian consensus on
450 irritable bowel syndrome. *Journal of gastroenterology and hepatology*. 2010;25(7):1189-205.
- 451 33. Hu P. Consensus on diagnosis and treatment of irritable bowel syndrome (2007, Changsha).
452 *Chinese Journal of General Practitioners*. 2008;7(5):298-300.
- 453 34. Li J, Chen J, Li Y. Consensus on the Diagnosis and Treatment of Functional Dyspepsia combined
454 Chinese and Western Medicine (2017). *Chinese Journal of Integrated Chinese and Western Medicine*
455 *digestion*. 2017(12):889-94.
- 456 35. Li J, Chen J, Tang X, Bian L. Consensus on the Diagnosis and Treatment of Irritable bowel
457 Syndrome by Integrated Traditional Chinese and Western Medicine (2017). *Chinese Journal of*
458 *Integrated Chinese and Western Medicine digestion*. 2018(3):227-32.
- 459 36. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of
460 monitoring irritable bowel syndrome and its progress. *Alimentary pharmacology & therapeutics*.
461 1997;11(2):395-402.
- 462 37. Li L, Wang H, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation,
463 and normalisation. *Journal of Epidemiology & Community Health*. 2003;57(4):259-63.
- 464 38. Chalmers RP. mirt: A Multidimensional Item Response Theory Package for the R Environment.
465 *Journal of Statistical Software*. 2012;48(6):1-29.
- 466 39. Chalmers RP. mirtCAT: computerized adaptive testing with multidimensional item response
467 theory <https://cran.r-project.org/web/packages/mirtCAT/index.html2017> [2020-3-8].
- 468 40. Rasmussen C. The infinite Gaussian mixture model. *Advances in neural information processing*
469 *systems*. 1999;12:554-60.
- 470 41. Pohl D, Van Oudenhove L, Törnblom H, Le Nevé B, Tack J, Simrén M. Functional Dyspepsia and
471 Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With
472 Irritable Bowel Syndrome. *Clin Gastroenterol Hepatol*. 2018;16(11):1745-53 e1.
- 473 42. Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut
474 pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year
475 population-based prospective study. *Aliment Pharmacol Ther*. 2016;44(6):592-600.
- 476 43. Larsson MB, Tillisch K, Craig AD, Engström M, Labus J, Naliboff B, et al. Brain responses to visceral
477 stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome.
478 *Gastroenterology*. 2012;142(3):463-72 e3.
- 479 44. Van Oudenhove L, Vandenbergh J, Dupont P, Geeraerts B, Vos R, Dirix S, et al. Regional brain
480 activity in functional dyspepsia: a H(2)(15)O-PET study on the role of gastric sensitivity and abuse
481 history. *Gastroenterology*. 2010;139(1):36-47.
- 482 45. McCullough RW. IBS, NERD and functional dyspepsia are immuno-neuronal disorders of mucosal
483 cytokine imbalances clinically reversible with high potency sucralfate. *Med Hypotheses*.
484 2013;80(3):230-3.
- 485 46. Lackner JM. The Role of Psychosocial Factors in Functional Gastrointestinal Disorders. *Frontiers of*
486 *Gastrointestinal Research*. 2014;33:104-16.
- 487 47. Byale A, Lennon RJ, Byale S, Breen-Lyles M, Edwinson AL, Gupta R, et al. High-Dimensional
488 Clustering of 4000 Irritable Bowel Syndrome Patients Reveals Seven Distinct Disease Subsets. *Clin*

489 Gastroenterol Hepatol. 2022.
490 48. Black CJ, Houghton LA, Ford AC. Latent class analysis does not support the existence of Rome IV
491 functional bowel disorders as discrete entities. *Neurogastroenterol Motil.* 2022;34(11):e14391.
492 49. Holtmann GJ, Talley NJ. Inconsistent symptom clusters for functional gastrointestinal disorders in
493 Asia: is Rome burning? *Gut.* 2018;67(11):1911-5.
494 50. Zinsmeister AR, Herrick LM, Saito Loftus YA, Schleck CD, Talley NJ. Identification and validation of
495 functional gastrointestinal disorder subtypes using latent class analysis: a population-based study.
496 *Scandinavian Journal of Gastroenterology.* 2018;53(5):549-58.
497
498

499

500 **Table 1 Framework of the theoretical model for assessment of FGIDs with 5 latent traits**

Index	Latent traits	Symptoms or factors for assessment
1	Systemic symptoms	Back Pain; Chest Pain; Joint Pain; Palpitations; Insomnia; Fatigue
2	Upper gastrointestinal symptoms	Bloating; Abdominal Cold; Heartburn; Belching; Nausea; Upper Abdominal Pain; Early Fullness
3	Lower gastrointestinal symptoms	Diarrhea; Lower Abdominal Pain; Loose Stool; Hyperactive Bowel Sounds; Urgency
4	Environmental sensitivity	Irregular Diet Trigger; Overwork Trigger; Indigestive Food Trigger; Excitant Food Trigger
5	Emotional disorders	Depression; Irritating; Anxiety; Stress

501

502 **Table 2 Demographics of the sample with FD and IBS**

Patient cohort		
Descriptives	Number of participants	996
	Number of female/male	532/464
	Percentage of females	53.41%
	Age	38.47(range 18-74)
Diagnosis	IBS	487(48.98%)
	FD	509(51.10%)
Duration (since first diagnosis)	0-1year	347(34.84%)
	1-3years	425(42.67%)
	More than 3 years	224(22.49%)

503

504

505 **Table 3 Comparison of intensity about each symptom between FD and IBS**

Items	Category	Subtypes of FGIDs		Z-score	p-value
		FD(n=509)	IBS(n=587)		
back pain	0	439	442	-2.26	*
	1	63	43		
	2	5	2		
	3	2	0		
chest pain	0	458	450	-1.32	0.19
	1	51	35		
	2	0	2		
joint pain	0	431	387	2.15	*
	1	74	94		
	2	4	4		
	3	0	2		
palpitations	0	372	348	0.51	0.61

	1	125	130		
	2	12	9		
	0	219	224		
insomnia	1	253	228	-0.86	0.39
	2	36	34		
	3	1	1		
	0	175	168		
fatigue	1	211	242	-1.64	0.11
	2	122	76		
	3	1	1		
	0	237	316		
bloating	1	194	150	-6.56	**
	2	73	17		
	3	5	4		
	0	428	407		
abdominal cold	1	66	53	0.38	0.71
	2	9	21		
	3	6	6		
	0	417	422		
heartburn	1	80	56	-2.03	*
	2	12	9		
	0	192	283		
belching	1	185	148	-7.17	**
	2	108	48		
	3	24	8		
	0	425	375		
nausea	1	72	97	2.55	*
	2	9	15		
	3	3	0		
	0	401	372		
upper abdominal pain	1	100	107	0.90	0.37
	2	8	8		
	0	327	333		
early fullness	1	104	102	-1.72	0.08
	2	67	48		
	3	11	4		
	0	392	75		
diarrhea	1	113	343	19.6	**
	2	2	61		
	3	2	8		

	0	412	207		
lower abdominal pain	1	97	280	12.5	**
	0	346	121		
loose stool	1	156	303	14.1	**
	2	7	49		
	3	0	14		
	0	483	361		
hyperactive bowel sounds	1	26	110	9.17	**
	2	0	14		
	3	0	2		
	0	430	216		
urgency	1	70	204	180.29	**
	2	5	37		
	3	4	30		
	0	327	372		
irregular diet trigger	1	182	114	-4.16	**
	2	0	1		
	0	340	326		
overwork trigger	1	169	161	-0.05	0.96
	0	246	247		
indigestive food trigger	1	263	240	-0.75	0.45
	0	291	296		
irritant food trigger	1	218	191	-1.16	0.25
	0	255	248		
depression	1	147	153	-0.68	0.50
	2	104	82		
	3	3	4		
	0	241	208		
irritating	1	144	179	0.46	0.65
	2	123	98		
	3	1	2		
	0	160	160		
anxiety	1	220	215	-0.79	0.43
	2	127	111		

	3	2	1		
	0	242	243		
stress	1	267	244	-0.74	0.46

506 Comparing severity of symptoms of FD and IBS patients using Mann-Whitney U test.

507 **:p<0.01,*:p<0.01

Table 4 Psychometric properties of each item of the self-report questionnaire

Item	MIDSC	Factor loadings				
		Systemic comorbidity	Upper gastrointestinal discomforts	Lower gastrointestinal symptoms	Environmental sensitivity	Psychological comorbidity
back pain	0.47	0.27	0.00	0.00	0.00	0.00
chest pain	0.52	0.29	0.00	0.00	0.00	0.00
joint pain	0.42	0.24	0.00	0.00	0.00	0.00
palpitations	0.480	0.27	0.00	0.00	0.00	0.00
insomnia	2.96	0.99	0.00	0.00	0.00	0.00
fatigue	2.95	0.87	0.00	0.00	0.00	0.00
bloating	1.54	0.00	0.67	0.00	0.00	0.00
abdominal cold	1.50	0.00	0.66	0.00	0.00	0.00
heartburn	1.18	0.00	0.57	0.00	0.00	0.00
belching	0.73	0.00	0.39	0.00	0.00	0.00
nausea	1.66	0.00	0.70	0.00	0.00	0.00
upper abdominal pain	0.79	0.00	0.42	0.00	0.00	0.00
early fullness	1.14	0.00	0.56	0.00	0.00	0.00
diarrhea	4.11	0.00	0.00	0.92	0.00	0.00
lower abdominal pain	1.45	0.00	0.00	0.65	0.00	0.00
loose stool	2.55	0.00	0.00	0.83	0.00	0.00
hyperactive bowel sounds	2.53	0.00	0.00	0.83	0.00	0.00
urgency	2.31	0.00	0.00	0.81	0.00	0.00
irregular diet trigger	0.70	0.00	0.00	0.00	0.38	0.00

overwork trigger	1.01	0.00	0.00	0.00	0.51	0.00
indigestive food trigger	4.74	0.00	0.00	0.00	0.94	0.00
excitant food trigger	0.95	0.00	0.00	0.00	0.49	0.00
depression	2.23	0.00	0.00	0.00	0.00	0.79
irritating	1.94	0.00	0.00	0.00	0.00	0.75
anxiety	4.08	0.00	0.00	0.00	0.00	0.92
stress	0.65	0.00	0.00	0.00	0.00	0.36

Table 5 Latent profile modelling result with computerized adaptive testing scores

Model	Classes	AIC	BIC	Entropy	prob_min	prob_max	n_min	n_max	BLRT_val	BLRT_p	LMRT_val	LMRT_p
1	1	38966.85	39275.78	39075.69	1	1	1	1	-	-	-	-
1	2	37374.27	37997.04	0.88	0.96	0.97	477/47.90%	519/52.10%	-19420.42	0	1716.69	<0.001
1	3	36402.54	37339.16	0.88	0.92	0.95	224/22.49%	422/42.37%	-18581.24	0	1139.36	<0.001
1	4	35894.10	37144.55	0.86	0.90	0.95	207/20.78%	311/31.23%	-18019.99	0	654.41	0.73

Table 6 Comparison of symptom severity among the 3-class subgroups estimated with latent profile analysis

Item content	Comparison between subgroups				
	Chi-square	df	Class 1-Class 2	Class 2-Class 3	Class 1-Class 3
back pain	126.35**	2	131.96**	8.11	140.07**
chest pain	115.78**	2	115.85**	0.79	115.06**
joint pain	219.38**	2	228.14**	37.44	58.93**
palpitations	139.33**	2	201.98**	3.30	198.68**
insomnia	60.48**	2	142.11**	18.52	160.64**
fatigue	32.28**	2	92.43**	49.79	58.93**
bloating	141.77**	2	162.06**	97.88**	259.94**
abdominal cold	292.39**	2	228.07**	21.26	249.33**
heartburn	80.25**	2	84.00**	55.39**	139.40**
belching	79.85**	2	73.35**	120.45**	193.80**

nausea	303.4**	2	247.74**	28.91	276.65**
upper abdominal pain	102.33**	2	171.44**	35.30	136.14**
early fullness	82.801**	2	134.19**	50.84**	185.03**
diarrhea	682.84**	2	364.01**	463.71**	99.69**
lower abdominal pain	312.21**	2	231.52**	294.21**	62.69**
loose stool	461.78**	2	331.13**	367.40**	36.28
hyperactive bowel sounds	131.62**	2	136.29**	129.05**	7.25
urgency	391.12**	2	351.71**	266.70**	85.01**
irregular diet trigger	16.03**	2	41.15	36.52	77.67**
overwork trigger	16.36**	2	47.04	34.07	81.10**
indigestive food trigger	84.07**	2	161.58**	22.42	183.99**
excitant food trigger	34.57**	2	81.73**	41.26	122.99**
depression	14.92**	2	80.93**	46.24	34.69
irritating	4.38	2	27.85	39.31	11.45
anxiety	6.39*	2	12.64	39.47	52.11
stress	29.14**	2	62.75**	51.88**	114.63**

Comparing severity of symptoms of subgroups using Kruskal-Wallis H test. **:p<0.01, *:p<0.05

Table 7 Proportion and Comparison of the clinical diagnosis of the 3-class latent class model

Group ID	n	Proportion	FD	IBS	Chi-square	P value
Class 1	224	22.49%	89	135		
Class 2	422	42.37%	357	65	354.54	<0.01
Class 3	350	35.14%	63	287		

Table 8 Property of the latent traits scores estimated in the computerized adaptive testing

Latent trait	Minimum	Mean	Maximum
Systemic comorbidity	-1.29	0.00	2.98
Upper gastrointestinal discomforts	-1.15	0.00	2.07
Lower gastrointestinal symptoms	-1.19	0.00	2.65
Environmental sensitivity	-1.12	0.01	1.92
Psychological comorbidity	-1.38	0.00	2.99

Table 9 Fitness indices of the latent profile models with multidimensional computerized adaptive testing scores

Classes	LogLik	AIC	BIC	SABIC	Entropy	prob_min	prob_max	n_min	n_max	BLRT_val	BLRT_p	LMRT_val	LMRT_p
1	-6184.8	12389.6	12438.6	12406.9	1.00	1.00	1.00	1	1	-	-	-	-
2	-5739.8	11511.6	11590.0	11539.2	1.00	1.00	1.00	492/49.50%	503/50.50%	-6184.82	0.00	869.06	<0.01
3	-5680.3	11404.6	11512.4	11442.6	0.91	0.75	1.00	89/8.94%	493/49.50%	-5739.80	0.00	116.20	<0.01
4	-5586.6	11229.2	11366.6	11277.6	0.95	0.97	0.99	201/20.18%	302/30.32%	-5680.30	0.00	182.90	<0.01
5	-5450.9	10969.9	11136.7	11028.7	0.98	0.97	1.00	48/4.82%	254/25.50%	-5586.65	0.00	264.92	<0.01
6	-5423.2	10926.4	11122.6	10955.5	0.95	0.73	1.00	48/4.82%	252/25.30%	-5450.99	0.00	54.20	<0.01
7	-5295.5	10683.0	10908.5	10762.4	0.98	0.93	1.00	24/2.41%	253/25.40%	-5328.29	0.00	64.05	<0.01
8	-5413.4	10930.9	11185.9	11020.7	0.90	0.56	1.00	5/0.005%	236/22.49%	-5470.95	0.00	-197.71	1.00

LogLik: Log-Likelihood(Loglik), AIC: Akaike Information Criteria, BIC: Bayesian Information Criteria, SABIC: Sample Adjusted BIC, BLRT: Bootstrap likelihood ratio test LMRT: Lo-Mendell-Rubin likelihood ratio test

Table 10 Proportion and Comparison of the clinical diagnosis of the 7-profile latent profile model

Subgroup ID	n	Proportion	FD	IBS	Chi-square	p-value
1	192	19.28%	92	100		
2	228	22.89%	117	111		
3	202	20.28%	97	105		
4	49	4.92%	30	19	11.391	0.08
5	48	4.82%	30	18		
6	253	25.40%	136	117		
7	24	2.41%	7	17		

Table 11 Comparison of latent traits severity among the 7-profile model with latent profile analysis

Factor	Chi-square(p value)	d f	Comparison between subgroups																				
			P1-P2	P1-P3	P1-P4	P1-P5	P1-P6	P1-P7	P2-P3	P2-P4	P2-P5	P2-P6	P2-P7	P3-P4	P3-P5	P3-P6	P3-P7	P4-P5	P4-P6	P4-P7	P5-P6	P5-P7	P6-P7
Systemic comorbidity	821.98**	6	526.52**	99.58	220.00**	808.91**	536.44**	806.91**	426.95	306.52**	282.38**	9.91	280.38**	120.43	709.33**	436.86**	707.33**	588.90**	316.43**	586.90**	272.47**	2.00	270.47**
Upper gastrointestinal	124.82**	6	94.04	157.14**	105.54	371.96**	254.31**	209.67	63.10	11.50	277.91**	160.26**	115.62	51.60	214.82**	97.17*	52.52	266.41	148.76	104.12	117.65	162.29	44.64

testinal																						
discomf																						
orts																						
Lower	17.678	6																				
gastroin	**																					
testinal			72.7	105.	38.8	97.4	72.3	159.	32.4	33.9	24.7											
sympto			7	23*	6	9	7	97	6	1	2	0.40										
ms																						
Environ	749.25	6																				
mental	**																					
sensitiv			21.7	500.	16.4	553.	516.	75.6	478.		531.	494.	53.8	484.	52.8	15.6	424.	536.	499.	59.1	37.2	477.
ity			3	47**	7	31**	09**	2	73**	5.26	57**	36**	9	00**	4	2	85**	84**	62**	5	1	69**
Psychol	79.327	6																				
ogical	**																					
comorb			151.	96.4	81.5	341.	157.	288.	54.9	69.9	190.											
idity			39**	1	0	80**	18**	48**	8	0	40**	5.79										

Comparing severity of symptoms of subgroups using Kruskal-Wallis H test. P1-P7:Profile 1-Profile 7, **:p<0.01,*:p<0.0




Figure 1 Characteristics of the 3-class latent class modelling of FD and IBS




Figure 2 Latent traits scores of the 7-profile latent profile modelling of FD and IBS

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	✓ (a) Indicate the study's design with a commonly used term in the title or the abstract
		✓ (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	✓ Explain the scientific background and rationale for the investigation being reported
Objectives	3	✓ State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	✓ Present key elements of study design early in the paper
Setting	5	✓ Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	✓ (a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	✓ Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	✓ For each variable of interest, give sources of data and

measurement		details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	✓ Describe any efforts to address potential sources of bias
Study size	10	✓ Explain how the study size was arrived at
Quantitative variables	11	✓ Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	<p>✓ (a) Describe all statistical methods, including those used to control for confounding</p> <p>✓ (b) Describe any methods used to examine subgroups and interactions</p> <p>✓ (c) Explain how missing data were addressed</p> <p>NA(d) If applicable, describe analytical methods taking account of sampling strategy</p> <p>✓ (e) Describe any sensitivity analyses</p>
Results		
Participants	13*	<p>✓ (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>✓ (b) Give reasons for non-participation at each stage</p>

NA (c) Consider use of a flow diagram		
Descriptive data	14*	<p>✓ (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <hr/> <p>✓ (b) Indicate number of participants with missing data for each variable of interest</p>
Outcome data	15*	<p>✓ Report numbers of outcome events or summary measures</p>
Main results	16	<p>✓ (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <hr/> <p>✓ (b) Report category boundaries when continuous variables were categorized</p> <hr/> <p>NA (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p>
Other analyses	17	<p>✓ Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p>
Discussion		
Key results	18	<p>✓ Summarise key results with reference to study objectives</p>
Limitations	19	<p>✓ Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</p>

Interpretation	20	✓ Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
----------------	----	--

Generalisability	21	✓ Discuss the generalisability (external validity) of the study results
------------------	----	---

Other information

Funding	22	✓ Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.